Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 13Neoplasm Metastasis 9Stomach Neoplasms 5Endometrial Neoplasms 4Pancreatic Neoplasms 3Ovarian Neoplasms 3Adenocarcinoma 3Salivary Gland Neoplasms 2Prostatic Neoplasms 2Esophageal Neoplasms 2Colorectal Neoplasms 2Brain Neoplasms 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Unresectable Locally Recurrent Breast Cancer 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Testicular Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Osteosarcoma 1Neoplasms 1Neoplasm, Residual 1Mouth Neoplasms 1Melanoma 1

Interventions

trastuzumab deruxtecan 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER2-Positive Primary Breast Cancer × trastuzumab deruxtecan × 30 days × Clear all
NCT04622319 2026-05-15

DESTINY-Breast05

Daiichi Sankyo

Phase 3 Active not recruiting
1,600 enrolled 1 FDA
Breast

HER2-Positive Primary Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡